Chinese companies’ seemingly remarkable progress has them leading the race for a coronavirus vaccine. Their speedy ascent has been unhindered by common scientific setbacks being reported by Western rivals, however, raising questions about how stringently they’re vetting results and reporting potential safety issues.
China has the largest number of candidates in late-stage vaccine trials, and its shots could be used by millions worldwide because President Xi Jinping has pledged to share successful ones overseas. But there is concern about Chinese developers’ standards and safeguards because some of their vaccines are being distributed in the country under an emergency use program before getting full regulatory approval.
AstraZeneca Plc and Johnson & Johnson temporarily halted testing earlier this year in the U.K. and the U.S., respectively, after a single participant in each trial got sick. In contrast, China’s science ministry has said its companies have inoculated about 60,000 volunteers in final-stage trials, but there have been no reports of serious adverse events.
One front-runner, China National Biotec Group Co., has said it’s vaccinated hundreds of thousands of people under the emergency use program, a sign of how widely Chinese shots are being administered without reports of serious adverse events. Yet scientists say the discovery of health problems is inevitable when so many people of all ages and with varying conditions are tested—even if the vaccine isn’t causing the illness.
This story is from the November 09, 2020 edition of Bloomberg Businessweek.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the November 09, 2020 edition of Bloomberg Businessweek.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Instagram's Founders Say It's Time for a New Social App
The rise of AI and the fall of Twitter could create opportunities for upstarts
Running in Circles
A subscription running shoe program aims to fight footwear waste
What I Learned Working at a Hawaiien Mega-Resort
Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.
Sustainability: Calamari's Climate Edge
Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment
Brazil Yanks the Welcome Mat for Oil Investors
Foreign oil majors have filed an injunction to halt a new tax on crude exports
POINT OF FAILURE
Silicon Valley Bank's collapse exposed a weakness in tech and in the broader economy
Glencore Stays the Course With Coal
The commodities giant’s CEO says the fossil fuel is still necessary, even as he pursues minerals needed for the energy transition
Under Pressure
History shows that when the Federal Reserve is raising rates, an unexpected shock can trigger a recession
Where the Ax Will Fall Next
Another week, another round of job cuts—this time Meta Platforms Inc. is adding to the 11,000 people it fired in November with thousands more, Bloomberg News has reported.
The Case for Ditching Your Wallet
Bellroy's clever phone carrier keeps those last crucial cards close.